ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

@article{Viviani2011ABVDVB,
  title={ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.},
  author={Simonetta Viviani and Pier Luigi Zinzani and Alessandro Rambaldi and Ercole Brusamolino and Alessandro Levis and Valeria Bonfante and Umberto Vitolo and Alessandro Pulsoni and Anna Marina Liberati and Giorgina Specchia and Pinuccia Valagussa and Andrea Rossi and Francesco Zaja and Enrico Maria Pogliani and Patrizia Pregno and Manuel Gotti and Andrea Gallamini and Delia Rota Scalabrini and Gianni Bonadonna and Alessandro Massimo Gianni},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 3},
  pages={
          203-12
        }
}
BACKGROUND BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). METHODS We randomly assigned 331 patients with previously untreated and unfavorable Hodgkin's lymphoma (stage IIB, III, or IV, or an international prognostic score of… 

Figures and Tables from this paper

Treatment of advanced-stage Hodgkin lymphoma.
TLDR
There are early data to suggest that starting with escalated BEACOPP may reduce the rate of recurrence after a negative interim PET to less than 10%, and this may be an attractive approach for those with very high-risk features at presentation, but risks overtreating many patients if applied nonselectively.
ABVD or BEACOPP for Advanced Hodgkin Lymphoma.
  • A. Engert
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
The next-generation trial in advanced-stage HL, HD15, in which more than 2,100 patients were randomly assigned, demonstrated the reduction to six cycles of BEACOPPescalated followed by radiation administered to residual positron emission tomography –positive disease led to a significantly improved and less toxic regimen.
Which Hodgkin’s Patients in the Unites States Should Be Treated with BEACOPP?
  • B. Cheson
  • Medicine
    Current Hematologic Malignancy Reports
  • 2014
TLDR
Given the comparable survival between BEACOPP and ABVD, as well as the greater toxicities of the former, including infertility, myelosuppression, and secondary malignancies, ABVD should remain the standard regimen for patients in the U.S.
HD2000 Update in Hodgkin Lymphoma-ABVD or BEACOPP?
TLDR
BEACOPP might result in better tumor control than ABVD, but this is at the expense of higher unrelated mortality, which may equalize overall survival, and in a network meta-analysis, six cycles of BEACopP at escalated doses were theoretically predicted to provide an absolute overall survival benefit over ABVD at 5 years.
To AVoiD bleomycin from Hodgkin’s regimen?
TLDR
The results showed that BV should not be given with bleomycin due to a high incidence of pulmonary toxicity and the combination of BV and AVD can be given safely and led to an impressive complete remission rate of 96%.
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
TLDR
The acceptable PFS and OS of chemosensitive patients with HL autografted after failure of upfront BEACOPP escalated seem to justify this approach.
ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy
  • S. JayaboseK. Viswanathan K. Rathnam
  • Medicine
    Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • 2016
TLDR
Both m-BEACOPP and ABVE-PC regimens have acceptable toxicity and offer promising response rate and relapse free survival without the need for radiation therapy in most patients; and thus may be considered for children with high-risk and intermediate-risk Hodgkin lymphoma.
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
TLDR
It is demonstrated that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL and these data are currently being confirmed in a multicenter randomized trial.
Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis
TLDR
Reduced progression/relapse, better CR, and similar OS were observed with BEACOPP, indicating its superior efficiency in the treatment of HL, but more analysis of treatment-related toxicity is needed.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
TLDR
Investigation of three combinations of chemotherapy for advanced Hodgkin's disease found increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD and standard BEACopP.
Is BEACOPP better than ABVD?
  • B. Cheson
  • Medicine
    Current hematologic malignancy reports
  • 2007
The majority of patients with advanced Hodgkin’s lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine). However, almost
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
TLDR
ABVD therapy for 6 to 8 months was as effective as 12 months of MopP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease.
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
TLDR
Preliminary results indicate that in terms of complete remission, ABVD could represent a successful alternative to MOPP to be used either in MopP failures or in sequential combination with MOPp, however, the lack of long‐term followup limits means an adequate comparison between the two treatments is not possible.
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
TLDR
ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin's disease and ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease.
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
  • M. FedericoS. Luminari P. Gobbi
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
BEACOPP is associated with a significantly improved PFS compared with ABVD, with a predictable higher acute toxicity, and was associated with higher rates of severe infections than ABVD and CEC.
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
TLDR
The high response rate, in particular the complete remission rate, the low toxicity profile, and the very high mobilizing potential of the IGEV regimen strongly suggest that patients with relapsed/refractory Hodgkin's lymphoma may benefit from the use of this salvage induction regimen.
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
  • A. EngertV. Diehl M. Löffler
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL, and challenges ABVD as standard of care for this patient population.
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
TLDR
There was no evidence of significant difference in EFS or OS between ABVD and MDRs in the trial overall or if the two MDR versus ABVD comparisons are considered separately, and ABVD remains the standard for treatment of advanced HL.
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
TLDR
This study confirms that I EV +/- HDT is a well-tolerated and effective salvage treatment for lymphoid malignancies, and that IEV acts as an excellent stem cell mobiliser.
...
...